Pierre-Joseph Royer

Dr. Pierre-Joseph Royer

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Blood
Verified
Journal Article
Closed access
PDF file
CCChristine Chauveau
Christine Chauveau
SRSéverine Rémy
Séverine Rémy
PRPierre-Joseph Royer
Pierre-Joseph Royer
MHMarcelo Hill
Marcelo Hill
STSéverine Tanguy-Royer
Séverine Tanguy-Royer
IAIgnacio Anegon
Ignacio Anegon
Heme oxygenase-1 (HO-1) is an intracellular enzyme that degrades heme and inhibits immune responses and inflammation in vivo. In most cell types, HO-1 is inducible by inflammatory stimuli and oxidative stress. Here we demonstrate that human monocyte-derived immature dendritic cells (iDCs) and several but not all freshly isolated rat splenic DC subsets and rat bone marrow-derived iDCs, spontaneously express HO-1. HO-1 expression drastically decreases during human and rat DC maturation induced in vitro. In human tissues, iDCs also express HO-1, whereas mature DCs do not. Induction of HO-1 expression with cobalt protoporphyrin (CoPP) in human and rat DCs inhibits lipopolysaccharide (LPS)-induced phenotypic maturation and secretion of proinflammatory cytokines, resulting in the inhibition of alloreactive T-cell proliferation. CoPP-treated DCs, however, retain the ability to produce the anti-inflammatory cytokine interleukin 10 (IL-10). Reactive oxygen species induced by LPS in DCs were inhibited by induction of HO-1. In conclusion, we identify, for the first time, the capacity of HO-1 to block maturation of DCs and to inhibit proinflammatory and allogeneic immune responses while preserving IL-10 production. This novel immune function for HO-1 may be of interest for the inhibition of immune responses in autoimmune diseases, transplantation, and other conditions involving activation of the immune system. (Blood. 2005;106:1694-1702)

1 August 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PRPierre-Joseph Royer
Pierre-Joseph Royer
MEMohamed Emara
Mohamed Emara
CYChaoxing Yang
Chaoxing Yang
AAAbeer Al-Ghouleh
Abeer Al-Ghouleh
PTPaddy Tighe
Paddy Tighe
AGAmir M Ghaemmaghami
Amir M Ghaemmaghami
The mannose receptor (MR) is a C-type lectin expressed by dendritic cells (DCs). We have investigated the ability of MR to recognize glycosylated allergens. Using a gene silencing strategy, we have specifically inhibited the expression of MR on human monocyte-derived DCs. We show that MR mediates internalization of diverse allergens from mite (Der p 1 and Der p 2), dog (Can f 1), cockroach (Bla g 2), and peanut (Ara h 1) through their carbohydrate moieties. All of these allergens bind to the C-type lectin-like carbohydrate recognition domains 4–7 of MR. We have also assessed the contribution of MR to T cell polarization after allergen exposure. We show that silencing MR expression on monocyte-derived DCs reverses the Th2 cell polarization bias, driven by Der p 1 allergen exposure, through upregulation of IDO activity. In conclusion, our work demonstrates a major role for MR in glycoallergen recognition and in the development of Th2 responses.

1 September 2016 in Transplantation
Verified
Journal Article
Closed access
PRPierre-Joseph Royer
Pierre-Joseph Royer
GOGustavo Olivera-Botello
Gustavo Olivera-Botello
AKAngela Koutsokera
Angela Koutsokera
JAJohn-David Aubert
John-David Aubert
EBEric Bernasconi
Eric Bernasconi
SCSysCLAD consortium
SysCLAD consortium
Chronic lung allograft dysfunction (CLAD) is the major limitation of long-term survival after lung transplantation. Chronic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently described restrictive allograft syndrome. Although numerous risk factors have been identified so far, the physiopathological mechanisms of CLAD remain poorly understood. We investigate here the immune mechanisms involved in the development of CLAD after lung transplantation. We explore the innate or adaptive immune reactions induced by the allograft itself or by the environment and how they lead to allograft dysfunction. Because current literature suggests bronchiolitis obliterans syndrome and restrictive allograft syndrome as 2 distinct entities, we focus on the specific factors behind one or the other syndromes. Chronic lung allograft dysfunction is a multifactorial disease that remains irreversible and unpredictable so far. We thus finally discuss the potential of systems-biology approach to predict its occurrence and to better understand its underlying mechanisms.

24 October 2007 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
MHMarcelo Hill
Marcelo Hill
STSéverine Tanguy‐Royer
Séverine Tanguy‐Royer
PRPierre-Joseph Royer
Pierre-Joseph Royer
CCChristine Chauveau
Christine Chauveau
KAKashif Asghar
Kashif Asghar
IAIgnacio Anegon
Ignacio Anegon
We have previously shown that human monocyte‐derived dendritic cells (DC) express indoleamine 2,3‐dioxygenase (IDO), as well as several other enzymes of the kynurenine pathway at the mRNA level upon maturation. The tolerogenic mechanisms of this pathway remain unclear. Here we show that LPS‐treated DC metabolize tryptophan as far as quinolinate. We found that IDO contributes to LPS and TNF‐α + poly(I:C)‐induced DC maturation since IDO inhibition using two different inhibitors impairs DC maturation. IDO knock‐down using short‐hairpin RNA also led to diminished LPS‐induced maturation. In line with these results, the tryptophan‐derived catabolites 3‐hydroxyanthranilic acid and 3‐hydroxykynurenine increased maturation of LPS‐treated DC. Concerning the molecular mechanisms of this effect, IDO acts as an intermediate pathway in LPS‐induced production of reactive oxygen species and NF‐κB activation, two processes that lead to DC maturation. Finally, we show that mature DC expand CD4+CD25high regulatory T cells in an IDO‐dependent manner. In conclusion, we show that IDO constitutes an intermediate pathway in DC maturation leading to expansion of CD4+CD25high regulatory T cells.

15 February 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SRSéverine Rémy
Séverine Rémy
PBPhilippe Blancou
Philippe Blancou
LTLaurent Tesson
Laurent Tesson
Virginie TardifVirginie Tardif
Virginie Tardif
RBRégis Brion
Régis Brion
CCChristine Chauveau
Christine Chauveau
Heme oxygenase-1 (HO-1) exerts its functions via the catabolism of heme into carbon monoxide (CO), Fe2+, and biliverdin, as well as by depletion of free heme. We have recently described that overexpression of HO-1 is associated with the tolerogenic capacity to dendritic cells (DCs) stimulated by LPS. In this study, we demonstrate that treatment of human monocyte-derived DCs with CO blocks TLR3 and 4-induced phenotypic maturation, secretion of proinflammatory cytokines, and alloreactive T cell proliferation, while preserving IL-10 production. Treatment of DCs with biliverdin, bilirubin, and deferoxamine or replenishing intracellular heme stores had no effect on DC maturation. HO-1 and CO inhibited LPS-induced activation of the IFN regulatory factor 3 pathway and their effects were independent of p38, ERK, and JNK MAPK. HO-1 and CO treatment also inhibited mouse DC maturation in vitro and mouse DC immunogenic properties in vivo, as shown by adoptive cell transfer in a transgenic model of induced diabetes. Thus, for the first time, our data show that CO treatment inhibits DC immunogenicity induced by TLR ligands and that blockade of IFN regulatory factor 3 is associated with this effect.

1 May 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TDTiphaine Delaunay
Tiphaine Delaunay
CACarole Achard
Carole Achard
NBNicolas Boisgerault
Nicolas Boisgerault
MGMarion Grard
Marion Grard
TPTacien Petithomme
Tacien Petithomme
JFJean-Francois Fonteneau
Jean-Francois Fonteneau